The FDA has expanded the approval of Jascayd (nerandomilast), an oral phosphodiesterase 4 (PDE4) inhibitor, to include treatment of progressive pulmonary fibrosis in adults.

Please provide your email address to receive an email when new articles are posted on . Pulmonary function testing results can indicate obstructive patterns. Providers must properly coach patients ...

Here are the top 5 most-read pulmonary fibrosis articles of 2025.

This combined model achieved a high level of accuracy, suggesting that imaging data alongside basic clinical information could be effective for screening.

Please provide your email address to receive an email when new articles are posted on . A smartphone-based tool that employs acoustic sensing and machine learning techniques is set to undergo testing.

The FDA has approved Jascayd (nerandomilast) as a treatment for a second lung disease, progressive pulmonary fibrosis, following the drug’s initial approval in October 2025 as a treatment for ...

The lung provides an extensive surface area mediating gas exchange between epithelial cells and the capillaries in the alveolus. Since lung cells are in direct contact with environmental gases and ...

The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary ...

A 40-year-old woman who was a frequent traveler suddenly found herself struggling to breathe after taking just a few steps. What began as unexplained fatigue and shortness of breath quickly disrupted ...